Orion Pharma Doses First Patient in Phase 1/2 Trial of Bispecific Antibody ODM-216

  • First patient dosed in Phase 1/2 BICIDES trial of ODM-216, a bispecific antibody targeting PVRIG and PD-L1 in advanced solid tumors.
  • ODM-216 is Orion Pharma’s first biologic and immuno-oncology candidate to reach clinical testing.
  • Trial registered on ClinicalTrials.gov under identifier NCT07805252.
  • Orion Pharma’s Biologics Research & Development Centre in Cambridge, UK, established in 2025, played a key role in advancing ODM-216.

Orion Pharma’s entry into clinical-stage biologics marks a strategic shift from small molecules to large molecules, aligning with broader industry trends toward immuno-oncology therapies. The company’s global R&D efforts, spanning Finland, the UK, and the US, underscore its commitment to diversifying its oncology pipeline. With net sales of EUR 1.89 billion in 2025, Orion Pharma is positioning itself to compete in the high-growth immuno-oncology space.

Clinical Progress
Whether ODM-216 demonstrates safety and preliminary anti-tumor activity in Phase 1/2 trial.
Pipeline Diversification
The pace at which Orion Pharma advances its pre-clinical immuno-oncology portfolio.
Biologics Capabilities
How Orion Pharma’s investment in biologics R&D translates into long-term competitive positioning.